In a previous study a partial inhibition of viral replication was observed in HBeAg-positive patients after acyclovir (ACV) treatment. To assess those results and to evaluate different treatment regimens, a randomized controlled trial with ACV given at 45 mg/kg/day by continuous infusion (in 5 pati
Immune therapy of hepatitis B virus chronic infection
✍ Scribed by Stanislas Pol; Marie-Louise Michel; Christian Bréchot
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 35 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
to be controlled for in comparing immunoprophylactic approaches. At present, DNA polymerase activity or HBV DNA is useful for estimating the level of exposure. In an editorial in this issue, Dr. Dienstag pointed out difficulties in comparing the results of two immunoprophylactic regimens conducted a
By routine screening for serologic markers of hepatitis A and B in patients with acute hepatitis, 30 chronic carriers of hepatitis B virus with serologic evidence of acute hepatitis A and two patients with simultaneous acute infection with hepatitis A virus and hepatitis B virus were detected. For
In the present study we have investigated 53 patients with a spectrum of acute and chronic hepatitis B virus (HBV) infection for the presence of leucocyte HBV-DNA with the aid of molecular techniques. HBV-DNA was detected in peripheral blood mononuclear cells of 31 of 45 (69%) of chronic HBsAg carri
Individuals with chronic hepatitis B virus (HBV)
Chronic hepatitis B virus (HBV) infection has a complicated course. Three phases are identified: an immune tolerant phase with high HBV DNA and normal alanine aminotransferase (ALT) levels associated with minimal liver disease; an immune active phase with high HBV DNA and elevated ALT levels with ac